Doximity DOCS Surges 81% on AI Search Economics

Doximity's stock nearly doubled after beating Q1 FY2027 revenue guidance and revealing AI Search unit economics that exceeded investor expectations for its healthcare SaaS platform.

Lead

What Happened

Doximity reported Q1 FY2027 revenue of $156.62 million, up 7% year-over-year and ahead of both the analyst consensus of $151.7 million and the high end of the company's own guidance band of $151–$152 million. Adjusted EBITDA of $74.8 million, representing a 48% margin, exceeded the company's guidance ceiling by eight percentage points. Non-GAAP earnings per share came in at $0.29, one cent below the $0.30 consensus — the only notable miss in the report.

Chief Executive Jeff Tangney framed the quarter around a single figure: AI Search, the company's AI-powered advertising platform for pharmaceutical and health-system clients, is generating more than ten times as much revenue per query as it costs to operate. That economics disclosure, combined with a sharp guidance raise, drove the after-hours move.

Guidance Raise Drives Rerating

Doximity lifted its full-year FY2027 revenue guidance to $671–$681 million from a prior range of $664–$676 million. For the fiscal second quarter, management guided to $170–$171 million in revenue and $80.5–$81.5 million in adjusted EBITDA — both above prior consensus estimates. Full-year EBITDA guidance was trimmed slightly to $309–$329 million as the company accelerates investment in AI infrastructure, but analysts focused on the revenue trajectory.

No AI Search revenue was recognized in Q1. Management signaled that the majority of contracted AI Search revenue is expected to begin flowing in Q3 FY2027, a deferred recognition dynamic that Piper Sandler described as reflecting a conservative posture, with the pipeline not yet embedded in guidance.

AI and Technology Angle

The AI narrative was central to investor reaction. Doximity's platform serves more than one million U.S. medical practitioners, representing an 80%-plus penetration of the domestic physician population. The company has signed 165 health-system AI clients and established 24-plus commercial programs with pharmaceutical companies using AI Search.

AI Scribe, the company's automated clinical note-writing tool, saw user adoption grow tenfold year-over-year as of July 2026. Nearly half of active workflow prescribers have adopted Doximity AI tools. Tangney also cited an independent clinical AI benchmark sponsored by Stanford and Harvard researchers — the NOHARM benchmark — in which Doximity's clinical AI assistant achieved a 4.8% clinical error rate, the lowest among U.S.-based models evaluated.

Market Reaction

The after-hours surge to $37.49 pulled back sharply during the next regular session, with shares opening at $38.87, reaching an intraday high of $40.00, and then retreating to close at $27.40 — a gain of 32.6%, or $6.74, from the prior close. Approximately 65 million shares traded hands, roughly 16 times the average daily volume.

A short squeeze amplified the move. Roughly 16–17% of the tradable float — approximately 20.7 million shares — was held short heading into earnings, and the gap-up forced rapid covering. Morgan Stanley upgraded the stock to Overweight from Equal Weight with a $53 price target, citing conservative guidance and underappreciated AI optionality. Price targets across the sell side moved meaningfully higher, with an aggregate consensus settling near $30–$32 following revisions.

Strategic Context

Doximity carries $687.8 million in cash and marketable securities with no debt, giving it substantial capacity to fund AI product development. The company repurchased $91.6 million in shares during Q1 alone against a $400 million remaining authorization.

Net revenue retention among the top 20 customers reached 112%, and the broader customer base showed 107% NRR. Customers generating more than $500,000 annually totaled 127, up 7% year-over-year, accounting for 83% of total revenue.

Outlook

Doximity's guidance raise and AI Search margin disclosure mark a meaningful shift in how investors are pricing the healthcare SaaS platform's AI transition. With the bulk of contracted AI Search revenue expected to begin hitting the income statement in Q3 FY2027 and AI Scribe adoption accelerating sharply, the nearer-term revenue trajectory appears more visible than it did before the Q1 report. The deferred AI revenue recognition and the gap between intraday highs and the closing price suggest markets are calibrating the timing carefully, with execution on AI Search commercialization the central variable for the remainder of the fiscal year.